Monika Lukoseviciute

Publications
CV
Public outreach and news

Articles

Article: MOLECULAR ONCOLOGY. 2026
Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model
Lukoseviciute M; Birgersson M; Ceriani P; Wilhelm M; Kostopoulou ON
Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;180:117500
Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro
Lukoseviciute M; Need E; Birgersson M; Dalianis T; Kostopoulou ON
Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;177:116993
Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model
Lukoseviciute M; Need E; Holzhauser S; Dalianis T; Kostopoulou ON
Article: ORAL ONCOLOGY. 2024;151:106749
Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival
Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylha C; Marklund L; Nasman A; Sivars L; Dalianis T
Article: ONCOLOGY REPORTS. 2023;50(3):166
Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
Lukoseviciute M; Holzhauser S; Pappa E; Mandal T; Dalianis T; Kostopoulou ON
Article: ONCOLOGY REPORTS. 2023;49(6):125
Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma
Lukoseviciute M; Theodosopoulou A; Holzhauser S; Dalianis T; Kostopoulou ON
Article: CANCERS. 2022;15(1):93
Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited
Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Article: VIRUSES-BASEL. 2022;14(7):1372
Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
Article: FRONTIERS IN ONCOLOGY. 2021;11:748657
Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
Lukoseviciute M; Maier H; Poulou-Sidiropoulou E; Rosendahl E; Holzhauser S; Dalianis T; Kostopoulou ON
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2021;58(2):211-225
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickstrom M; Kostopoulou ON; Dalianis T
Article: ANTICANCER RESEARCH. 2020;40(1):53-66
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickstrom M; Kostopoulou ON

All other publications

Doctoral thesis: 2025
Novel strategies of optimal combinations of targeted therapy in medulloblastoma and neuroblastoma
Lukoseviciute M
Review: ANTICANCER RESEARCH. 2023;43(9):3829-3839
New Approaches Towards Targeted Therapy for Childhood Neuroblastoma
Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON

Employments

Postdoctoral Researcher, Department of Oncology-Pathology, Karolinska Institutet, 2026-2028
Phd Student, Department of Oncology-Pathology, Karolinska Institutet, 2022-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2025
Degree Of Master Of Medical Science 120 Credits, Karolinska Institutet, 2022
Degree Of Bachelor Of Medical Science, Karolinska Institutet, 2020

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI